Abstract:Objective: This study aims to investigate the diagnostic performance of serum high sensitivity C-reactive protein (CRP), urinary retinol-binding protein (RBP), and beta 2 microglobulin (beta 2-MG) for diabetic microangiopathy. Methods: A total of 146 patients with diabetes admitted to our hospital from February 2016 to February 2019 were selected as subjects. Among them, 76 patients with microvascular disease were included in the study group, and the other 70 patients without microvascular disease were enrolled in the control group. 5 mL of venous blood was collected before and after treatment, which was placed at room temperature for 30 min and centrifuged (4000 rpm/min) for 10 min to obtain upper serum. The serum beta 2-MG and RBP levels were measured using chemiluminescence and immunoturbidimetry, respectively, and the CRP levels were measured using a fully automated specialty protein analyzer. The clinical efficacy of the treatment was recorded. The diagnostic value of the combined RBP, beta 2-MG, and CRP for diabetic microangiopathy was analyzed using an ROC curve. The predictive value of combined RBP, beta 2-MG, and CRP for therapeutic outcomes was also analyzed using an ROC curve. The risk factors associated with diabetic microangiopathy were analyzed as well. Results: The serum levels of RBP, beta 2-MG, and CRP in the study group were significantly higher than they were in the control group (P<0.05), but after treatment, there were no significant differences in the serum levels of RBP, beta 2-MG, and CRP in both groups (P>0.05), and the RBP level was still higher than it was in the control group (P<0.05). After treatment, the serum levels of RBP, beta 2-MG, and CRP decreased in both groups compared with the levels before treatment (P<0.05). According to an ROC curve analysis, the diagnostic sensitivity for diabetic microangiopathy was 86.00%, and the specificity was 94.00% (P<0.001). The effective sensitivity for diabetic microangiopathy patients was 80.00%, and the specificity was 90.00% (P<0.001). A logistic regression analysis showed that RBP, beta 2-MG, and CRP are independent protective factors for diabetic microangiopathy (OR>1, P<0.05). Conclusion: The serum levels of beta 2-MG, RBP, and CRP in patients with diabetic microangiopathy are higher than they are in healthy populations. The combined measurement of beta 2-MG, RBP, and CRP has a good efficacy in the diagnosis and prediction of the treatment outcomes of diabetic microangiopathy.

Circulating β2 and α1 microglobulins predict progression of nephropathy in diabetic patients: a meta-analysis of prospective cohort studies

Negative Correlation of Serum Total Bile Acid with Albuminuria in Patients with Type 2 Diabetes Mellitus: A Cross-sectional Study.

The potential of cardiac biomarkers, NT-ProBNP and troponin T, in predicting the progression of nephropathy in diabetic patients: A meta-analysis of prospective cohort studies

Role of serum β2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy

Urinary RBP As an Independent Predictor of Renal Outcome in Diabetic Nephropathy.

Evaluating new biomarkers for diabetic nephropathy: Role of α2-macroglobulin, podocalyxin, α-L-fucosidase, retinol-binding protein-4, and cystatin C

MicroRNAs in the Progress of Diabetic Nephropathy: A Systematic Review and Meta-Analysis

Mannose-binding lectin activation is associated with the progression of diabetic nephropathy in type 2 diabetes mellitus patients

Clinical markers and some trace elements in patients with type-2 diabetic nephropathy : Impact of insulin resistance.

The effects of 2-MG, RBP, and CRP on the diagnosis and prediction of the treatment outcomes of diabetic microangiopathy

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria

Angiopoietin-2 and Angiopoietin-like Proteins with a Prospective Role in Predicting Diabetic Nephropathy

Relationship between circulating thrombospondin‐1 messenger ribonucleic acid and microribonucleic acid‐194 levels in Chinese patients with type 2 diabetic kidney disease: The outcomes of a case–control study

Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease

Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics

The implication of miR-200a and miR-132 expression and their correlations with NF-κB/TNF-alpha signaling in adults with diabetic nephropathy

Circulating metabolites improve the prediction of renal impairment in patients with type 2 diabetes

Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy

Serum Podoplanin Levels as a Potential Biomarker for Diabetic Nephropathy Progression: A Cross-Sectional Study

Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker

Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes